Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration-Reference-Cited by-同舟云学术

Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration

Published:2020-10 Issue: Volume:218 Page:225-241
ISSN:0002-9394
Container-title:American Journal of Ophthalmology
language:en
Short-container-title:American Journal of Ophthalmology

Author:

Brown Gary C.^ORCID,Brown Melissa M.,Rapuano Sara,Boyer David

Publisher

Elsevier BV

Subject

Ophthalmology

Reference67 articles.

1. Ranibizumab for neovascular age-related macular degeneration;Rosenfeld;N Engl J Med,2006

2. Ranibizumab versus verteporfin for neovascular age-related macular degeneration;Brown;N Engl J Med,2006

3. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration;Heier;Ophthalmology,2012

4. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies;Schmidt-Erfurth;Ophthalmology,2014

5. HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration;Dugel;Ophthalmology,2019

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ocular neurodegenerative disorders;A Review on Diverse Neurological Disorders;2024

2. Cost-Utility Analysis of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration;Ophthalmology Retina;2023-11

3. Prevention Surpasses Treatment: 5-year Follow-Up, Cost-Utility, and Cost–Benefit of Zeaxanthin Therapy for Neovascular Age-Related Macular Degeneration;Ophthalmology and Therapy;2023-07-10

4. Complement inhibitors for age-related macular degeneration;Cochrane Database of Systematic Reviews;2023-06-14

5. Influence of lesion location on lesion reactivation after initial treatment in neovascular age-related macular degeneration;Graefe's Archive for Clinical and Experimental Ophthalmology;2023-06-14